PL4004002T3 - Związki makrocykliczne jako agoniści sting i sposoby oraz ich zastosowania - Google Patents
Związki makrocykliczne jako agoniści sting i sposoby oraz ich zastosowaniaInfo
- Publication number
- PL4004002T3 PL4004002T3 PL20768090.1T PL20768090T PL4004002T3 PL 4004002 T3 PL4004002 T3 PL 4004002T3 PL 20768090 T PL20768090 T PL 20768090T PL 4004002 T3 PL4004002 T3 PL 4004002T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- macrocyclic compounds
- sting agonists
- sting
- agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921029556 | 2019-07-22 | ||
| IN201921051086 | 2019-12-10 | ||
| IN202021003961 | 2020-01-29 | ||
| PCT/IB2020/056875 WO2021014365A1 (en) | 2019-07-22 | 2020-07-22 | Macrocyclic compounds as sting agonists and methods and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4004002T3 true PL4004002T3 (pl) | 2024-11-18 |
Family
ID=72422197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20768090.1T PL4004002T3 (pl) | 2019-07-22 | 2020-07-22 | Związki makrocykliczne jako agoniści sting i sposoby oraz ich zastosowania |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US12479858B2 (pl) |
| EP (1) | EP4004002B1 (pl) |
| JP (1) | JP7592689B2 (pl) |
| KR (1) | KR20220035955A (pl) |
| CN (1) | CN114174303B (pl) |
| AU (1) | AU2020319058B2 (pl) |
| BR (1) | BR112022001125A2 (pl) |
| CA (1) | CA3147397A1 (pl) |
| CL (1) | CL2022000145A1 (pl) |
| CO (1) | CO2022001814A2 (pl) |
| CR (1) | CR20220029A (pl) |
| DK (1) | DK4004002T3 (pl) |
| EC (1) | ECSP22005485A (pl) |
| ES (1) | ES2989915T3 (pl) |
| FI (1) | FI4004002T3 (pl) |
| GE (2) | GEP20247627B (pl) |
| HR (1) | HRP20241222T1 (pl) |
| HU (1) | HUE068456T2 (pl) |
| IL (1) | IL289740B2 (pl) |
| LT (1) | LT4004002T (pl) |
| MA (1) | MA56674B1 (pl) |
| MX (1) | MX420195B (pl) |
| PE (1) | PE20220937A1 (pl) |
| PH (1) | PH12022550175A1 (pl) |
| PL (1) | PL4004002T3 (pl) |
| PT (1) | PT4004002T (pl) |
| RS (1) | RS66126B1 (pl) |
| SA (1) | SA522431429B1 (pl) |
| SI (1) | SI4004002T1 (pl) |
| SM (1) | SMT202400399T1 (pl) |
| UA (1) | UA129653C2 (pl) |
| WO (1) | WO2021014365A1 (pl) |
| ZA (1) | ZA202201375B (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7664680B2 (ja) | 2017-03-29 | 2025-04-18 | リガケム バイオサイエンシズ， インク． | ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物 |
| CN114127054B (zh) | 2019-07-22 | 2024-04-09 | 勃林格殷格翰国际有限公司 | 作为用于治疗炎性气道或纤维化疾病的自分泌运动因子(atx)调节剂的n-甲基、n-(6-(甲氧基)哒嗪-3-基)胺衍生物 |
| JP2022543086A (ja) | 2019-08-02 | 2022-10-07 | メルサナ セラピューティクス インコーポレイテッド | がんの処置用のＳＴＩＮＧ（インターフェロン遺伝子刺激因子）アゴニストとしてのビス－［Ｎ－（（５－カルバモイル）－１Ｈ－ベンゾ［ｄ］イミダゾール－２－イル）－ピラゾール－５－カルボキサミド］誘導体および関連化合物 |
| JP2023520513A (ja) | 2020-04-02 | 2023-05-17 | メルサナ セラピューティクス インコーポレイテッド | Ｓｔｉｎｇアゴニストを含む抗体薬物コンジュゲート |
| WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
| US20240116909A1 (en) * | 2021-01-12 | 2024-04-11 | Jacobio Pharmaceuticals Co., Ltd. | Novel compounds useful as sting agonists and uses thereof |
| MX2023008327A (es) * | 2021-01-15 | 2023-08-22 | Seagen Inc | Anticuerpos inmunomoduladores de anticuerpo-farmaco. |
| AU2023407213A1 (en) * | 2022-12-22 | 2025-07-03 | Aculeus Therapeutics Pty Ltd | Benzimidazole derivatives for the modulation of sting |
| WO2025012057A1 (en) * | 2023-07-07 | 2025-01-16 | F. Hoffmann-La Roche Ag | Macrocycles for the treatment of autoimmune disease |
| AR133266A1 (es) * | 2023-07-19 | 2025-09-10 | Hoffmann La Roche | Macrociclos para el tratamiento de enfermedades autoinmunitarias |
| CN119490423A (zh) * | 2023-08-15 | 2025-02-21 | 沈阳中化农药化工研发有限公司 | 一种制备2-氟-3-氨基苯甲酸及其酯类化合物的方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20010395A1 (it) | 2001-02-27 | 2002-08-27 | Dompe Spa | Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate |
| AR046959A1 (es) | 2003-12-18 | 2006-01-04 | Tibotec Pharm Ltd | Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio |
| US7488736B2 (en) | 2004-05-17 | 2009-02-10 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| GEP20125456B (en) | 2005-10-07 | 2012-03-26 | Exelixis Inc | Azetidines as mek inhibitors for the treatment of proliferative diseases |
| KR20090019011A (ko) | 2006-06-15 | 2009-02-24 | 베링거 인겔하임 인터내셔날 게엠베하 | 단백질 키나아제 ｃ-알파의 억제제로서의 2-아닐리노-4-(헤테로사이클릭)아미노-피리미딘 |
| WO2008090570A1 (en) | 2007-01-25 | 2008-07-31 | Panacea Biotec Ltd | Novel antimicrobials |
| TW201000447A (en) | 2008-05-30 | 2010-01-01 | Astrazeneca Ab | New compounds useful in pain therapy |
| WO2011091446A1 (en) * | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Chemical compounds |
| US20140364617A1 (en) * | 2010-12-15 | 2014-12-11 | Abbvie Inc. | Anti-viral compounds |
| SG11201505120UA (en) | 2012-12-28 | 2015-08-28 | Nippon Zoki Pharmaceutical Co | Cinnamic acid amide derivative |
| CR20160564A (es) * | 2014-06-04 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos cíclicos como moduladores de sting |
| US20180147187A1 (en) | 2015-01-12 | 2018-05-31 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| EP3325473A4 (en) | 2015-07-22 | 2019-06-26 | The Royal Institution for the Advancement of Learning / McGill University | Compounds and uses thereof in the treatment of cancer and other medical disorders |
| WO2017175156A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| IL295649B2 (en) | 2016-04-07 | 2025-12-01 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
| CN111689959B (zh) | 2016-05-27 | 2022-04-01 | 石药集团中奇制药技术（石家庄）有限公司 | 作为fgfr4抑制剂的杂环化合物 |
| EA036338B1 (ru) * | 2017-02-22 | 2020-10-28 | Глэксосмитклайн Интеллекчуал Проперти Девелопмент Лимитед | Гетероциклические амиды, пригодные в качестве модуляторов белков |
| US20200138827A1 (en) | 2017-06-22 | 2020-05-07 | Curadev Pharma Limited | Small molecule modulators of human sting |
| PE20200696A1 (es) | 2017-06-22 | 2020-06-16 | Curadev Pharma Ltd | Moduladores de moleculas pequenas de sting humana |
| JP2020524718A (ja) | 2017-06-22 | 2020-08-20 | キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ | ヒトｓｔｉｎｇの複素環式小分子調節因子 |
| JP7274478B2 (ja) | 2017-07-27 | 2023-05-16 | スティングレイ・セラピューティクス・インコーポレイテッド | 置換された－３Ｈ－イミダゾ［４，５－ｃ］ピリジン及び１Ｈ－ピロロ［２，３－ｃ］ピリジンシリーズの新規なエクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ－１（ＥＮＰＰ１）並びにがん免疫治療薬としてのインターフェロン遺伝子（ＳＴＩＮＧ）モジュレータのための刺激剤 |
| AU2018311965A1 (en) | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment |
| CA3071538A1 (en) | 2017-08-04 | 2019-02-07 | Merck Sharp & Dohme Corp. | Benzo[b]thiophene sting agonists for cancer treatment |
| JP7291130B2 (ja) | 2017-10-05 | 2023-06-14 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | インターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質 |
| EP3692033A1 (en) | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) useful in treating hiv |
| WO2020132582A1 (en) * | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting agonists and uses thereof |
| KR20210146370A (ko) | 2019-03-28 | 2021-12-03 | 루핀 리미티드 | Sting 효능제로서의 매크로사이클릭 화합물 |
-
2020
- 2020-07-22 RS RS20241052A patent/RS66126B1/sr unknown
- 2020-07-22 HR HRP20241222TT patent/HRP20241222T1/hr unknown
- 2020-07-22 PT PT207680901T patent/PT4004002T/pt unknown
- 2020-07-22 PL PL20768090.1T patent/PL4004002T3/pl unknown
- 2020-07-22 CA CA3147397A patent/CA3147397A1/en active Pending
- 2020-07-22 JP JP2022504707A patent/JP7592689B2/ja active Active
- 2020-07-22 UA UAA202200745A patent/UA129653C2/uk unknown
- 2020-07-22 SM SM20240399T patent/SMT202400399T1/it unknown
- 2020-07-22 IL IL289740A patent/IL289740B2/en unknown
- 2020-07-22 MA MA56674A patent/MA56674B1/fr unknown
- 2020-07-22 AU AU2020319058A patent/AU2020319058B2/en active Active
- 2020-07-22 CR CR20220029A patent/CR20220029A/es unknown
- 2020-07-22 MX MX2022000939A patent/MX420195B/es unknown
- 2020-07-22 SI SI202030501T patent/SI4004002T1/sl unknown
- 2020-07-22 ES ES20768090T patent/ES2989915T3/es active Active
- 2020-07-22 HU HUE20768090A patent/HUE068456T2/hu unknown
- 2020-07-22 US US17/628,619 patent/US12479858B2/en active Active
- 2020-07-22 PE PE2022000120A patent/PE20220937A1/es unknown
- 2020-07-22 BR BR112022001125A patent/BR112022001125A2/pt unknown
- 2020-07-22 LT LTEPPCT/IB2020/056875T patent/LT4004002T/lt unknown
- 2020-07-22 GE GEAP202015883A patent/GEP20247627B/en unknown
- 2020-07-22 KR KR1020227005943A patent/KR20220035955A/ko not_active Ceased
- 2020-07-22 PH PH1/2022/550175A patent/PH12022550175A1/en unknown
- 2020-07-22 CN CN202080053237.XA patent/CN114174303B/zh active Active
- 2020-07-22 DK DK20768090.1T patent/DK4004002T3/da active
- 2020-07-22 EP EP20768090.1A patent/EP4004002B1/en active Active
- 2020-07-22 WO PCT/IB2020/056875 patent/WO2021014365A1/en not_active Ceased
- 2020-07-22 FI FIEP20768090.1T patent/FI4004002T3/fi active
- 2020-07-22 GE GEAP202415883A patent/GEAP202415883A/en unknown
-
2022
- 2022-01-19 SA SA522431429A patent/SA522431429B1/ar unknown
- 2022-01-21 EC ECSENADI20225485A patent/ECSP22005485A/es unknown
- 2022-01-21 CL CL2022000145A patent/CL2022000145A1/es unknown
- 2022-01-28 ZA ZA2022/01375A patent/ZA202201375B/en unknown
- 2022-02-21 CO CONC2022/0001814A patent/CO2022001814A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202201375B (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
| IL304704A (en) | Compounds and methods for targeted reduction of rapidly accelerated polypeptide fibrosarcoma | |
| IL288104A (en) | Heterocyclic compounds, preparation methods and their use | |
| IL271964A (en) | Macrocyclic compounds and their uses | |
| EP3774765A4 (en) | Aza-benzothiophene compounds as sting agonists | |
| PL3599868T3 (pl) | Chwastobójcza mieszanina, kompozycja i sposób | |
| IL286526A (en) | Macrocyclic compounds as sting agonists | |
| IL288991A (en) | A macrocyclic compound and its uses | |
| GB201617572D0 (en) | Use, method, kit, composition and antibodies | |
| EP3387701A4 (en) | MAGNETIC INSULATION, MANUFACTURING METHOD THEREOF AND DEVICE CONTAINING SAME | |
| GB201705124D0 (en) | Composition, method and use | |
| GB2564511B (en) | Composition, method and use | |
| SG11202105125XA (en) | Macrocyclic compound and use thereof | |
| GB201619705D0 (en) | Sliding component, material and method | |
| GB201805016D0 (en) | Composition, method and use | |
| SG10201603101YA (en) | Lubricant composition, and preparation method and use thereof | |
| PL3448555T3 (pl) | Stała kompozycja oczyszczająca, sposób jej otrzymywania i jej zastosowania | |
| HK40063843A (en) | Macrocyclic compounds as sting agonists | |
| GB201908967D0 (en) | Macrocyclic compounds and uses thereof | |
| GB201810121D0 (en) | Macrocyclic compounds and uses thereof | |
| HK40032561A (en) | Macrocyclic compounds and uses thereof | |
| HK40015378A (en) | Cyclic dinucleotides as sting agonists | |
| HK40016691A (en) | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | |
| GB201716557D0 (en) | Composition, methods and uses | |
| GB201610992D0 (en) | Method, composition and sensor |